Country for PR: United States
Contributor: PR Newswire New York
Tuesday, June 04 2019 - 23:17
Cellenkos, Inc. Initiates Phase 1 Clinical Trial of CK0801 for Treatment of Bone Marrow Failure Syndromes
HOUSTON, June 4, 2019 /PRNewswire-AsiaNet/ --

Cellenkos, Inc.(, announced today the initiation 
of a Phase 1 Clinical Trial of CK0801, a first-in-class, allogeneic cord 
blood-derived T-regulatory cell product, for treatment of patients with bone 
marrow failure syndromes, including aplastic anemia, hypoplastic 
myelodysplasia, and primary myelofibrosis.  These syndromes are characterized 
by uncontrolled attack of disease-driving cytotoxic T-cells that lead to an 
inflammatory microenvironment and inhibition of normal blood cell production in 
the bone marrow.  CK0801 delivers healthy regulatory T-cells that home to sites 
of bone marrow inflammation and suppress the cytotoxic T-cells, allowing 
normalization of blood cell production.   

Photo - 
Logo - 

"This Phase 1 trial of CK0801 in bone marrow failure syndromes represents an 
important milestone for Cellenkos," said Elizabeth J. Read, MD, Chief 
Technology Officer at Cellenkos.  "Cellenkos' programs include development of 
cord blood-derived T-regulatory cell products for clinical application to 
hematologic diseases, graft vs. host disease, neuro-inflammatory disorders, and 
autoimmune diseases.  We aim to demonstrate that this novel cellular product is 
not only safe, but also capable of providing transformative clinical benefit to 
a range of serious illnesses."

The Phase 1 clinical trial of CK0801 in bone marrow failure syndromes will be 
led by Tapan Kadia, MD, Associate Professor of Leukemia at The University of 
Texas MD Anderson Cancer Center ( 
) in Houston, Texas. 

About Bone Marrow Failure Syndromes
Bone marrow failure syndrome refers to a group of life-threatening diseases 
with defective production of red blood cells (which leads to anemia), white 
blood cells (which leads to severe infections), and platelets (which leads to 
bleeding).  Increasing evidence supports the role of immune dysfunction and 
uncontrolled inflammation, as well as defective T-regulatory cells, in the 
generation and propagation of bone marrow failure syndromes.  This inflammatory 
process can be reversed by normal T-regulatory cells, leading to improved bone 
marrow function, which may translate into clinical benefit.  Bone marrow 
failure remains an incurable disease except for those patients who are eligible 
to receive an allogeneic stem cell transplantation.  

About CK0801
CK0801, is a first-in-class, allogeneic, cord blood-derived T-regulatory cell 
product, developed from Cellenkos' proprietary manufacturing platform, that 
overcomes immune dysfunction by inhibiting key drivers of inflammation.   
CK0801 contains robust regulatory T-cells derived from healthy donor cord blood 
units, and is manufactured at Cellenkos' GMP manufacturing facility in Houston, 
Texas.  The first CK0801 IND was approved by the U.S. Food and Drug 
Administration (FDA) in June 2018.  

About Cellenkos, Inc.
Cellenkos is a clinical-stage biotechnology company focused on cord 
blood-derived T-regulatory cellular therapies for the treatment of autoimmune 
diseases and inflammatory disorders.  Cellenkos was founded on technologies 
arising from the laboratory investigations of Simrit Parmar, MD, Associate 
Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer 

For more information, please visit
Erin Horne
+1 832-962-7628
SOURCE: Cellenkos, Inc.